(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a leading cell therapy company developing Tovaxin® for multiple sclerosis (MS), today announced the successful completion of two separate meetings with the U.S. Food and Drug Administration (FDA) regarding the Company’s planned development program for Tovaxin. Based on positive feedback from the FDA, Opexa believes it is now positioned from a regulatory perspective to advance with a pivotal Phase 3 clinical study of Tovaxin in MS. The Company is in the process of completing necessary preparations to be able to initiate such a study.
